| Agata Joanna Sajkiewicz, MD | |
|
34 Maple St, Norwalk Hospital, Norwalk, CT 06850-3815 | |
| (203) 852-2471 | |
| Not Available |
| Full Name | Agata Joanna Sajkiewicz |
|---|---|
| Gender | Female |
| Speciality | Internal Medicine |
| Experience | 15 Years |
| Location | 34 Maple St, Norwalk, Connecticut |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1134357742 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | XXXXXXXXX (Connecticut) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Hartford Hospital | Hartford, CT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Hartford Hospital | 2567366016 | 827 |
| Hartford Healthcare Medical Group Specialists Pllc | 3173866241 | 1138 |
News Archive
Children who suffer from Hutchinson-Gilford Progeria syndrome age prematurely due to a defective protein in their cells. Scientists at Technische Universität München have now identified another important pathological factor: the system responsible for removing cellular debris and for breaking down defective proteins operates at lower levels in HGPS cells than in normal cells. The researchers have succeeded in reactivating protein breakdown in HGPS cells and thus reducing disease-related defects by using a substance from broccoli.
New York Blood Center (NYBC), serving more than 20 million people in New York City, Long Island, the Hudson Valley, and New Jersey, calls upon our communities to please donate blood and platelets, after our tally of blood donations lost due to the weather doubled overnight – to more than 2,000.
Haiti, the U.S. and other international partners on Monday launched "a nationwide vaccination campaign in the Caribbean country that seeks to curb or prevent infectious diseases, health officials said," the Associated Press/Fox News reports.
Spectral Diagnostics Inc., a Phase III company seeking FDA approval for its lead theranostics product for the treatment severe sepsis and septic shock, today announced initiation of its U.S. pivotal trial of Toraymyxin™, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream, for patients with severe sepsis.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. announced today that it has submitted a New Drug Application to the U.S. Food and Drug Administration for rivaroxaban, an investigational, oral, once-daily anticoagulant, for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation.
› Verified 4 days ago
| Entity Name | Hartford Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1407806391 PECOS PAC ID: 2567366016 Enrollment ID: O20031125000700 |
News Archive
Children who suffer from Hutchinson-Gilford Progeria syndrome age prematurely due to a defective protein in their cells. Scientists at Technische Universität München have now identified another important pathological factor: the system responsible for removing cellular debris and for breaking down defective proteins operates at lower levels in HGPS cells than in normal cells. The researchers have succeeded in reactivating protein breakdown in HGPS cells and thus reducing disease-related defects by using a substance from broccoli.
New York Blood Center (NYBC), serving more than 20 million people in New York City, Long Island, the Hudson Valley, and New Jersey, calls upon our communities to please donate blood and platelets, after our tally of blood donations lost due to the weather doubled overnight – to more than 2,000.
Haiti, the U.S. and other international partners on Monday launched "a nationwide vaccination campaign in the Caribbean country that seeks to curb or prevent infectious diseases, health officials said," the Associated Press/Fox News reports.
Spectral Diagnostics Inc., a Phase III company seeking FDA approval for its lead theranostics product for the treatment severe sepsis and septic shock, today announced initiation of its U.S. pivotal trial of Toraymyxin™, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream, for patients with severe sepsis.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. announced today that it has submitted a New Drug Application to the U.S. Food and Drug Administration for rivaroxaban, an investigational, oral, once-daily anticoagulant, for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation.
› Verified 4 days ago
| Entity Name | Hartford Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1770696643 PECOS PAC ID: 2567366016 Enrollment ID: O20031125000752 |
News Archive
Children who suffer from Hutchinson-Gilford Progeria syndrome age prematurely due to a defective protein in their cells. Scientists at Technische Universität München have now identified another important pathological factor: the system responsible for removing cellular debris and for breaking down defective proteins operates at lower levels in HGPS cells than in normal cells. The researchers have succeeded in reactivating protein breakdown in HGPS cells and thus reducing disease-related defects by using a substance from broccoli.
New York Blood Center (NYBC), serving more than 20 million people in New York City, Long Island, the Hudson Valley, and New Jersey, calls upon our communities to please donate blood and platelets, after our tally of blood donations lost due to the weather doubled overnight – to more than 2,000.
Haiti, the U.S. and other international partners on Monday launched "a nationwide vaccination campaign in the Caribbean country that seeks to curb or prevent infectious diseases, health officials said," the Associated Press/Fox News reports.
Spectral Diagnostics Inc., a Phase III company seeking FDA approval for its lead theranostics product for the treatment severe sepsis and septic shock, today announced initiation of its U.S. pivotal trial of Toraymyxin™, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream, for patients with severe sepsis.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. announced today that it has submitted a New Drug Application to the U.S. Food and Drug Administration for rivaroxaban, an investigational, oral, once-daily anticoagulant, for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation.
› Verified 4 days ago
| Entity Name | Norwalk Hospital Association |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1427041581 PECOS PAC ID: 3375436660 Enrollment ID: O20040202000988 |
News Archive
Children who suffer from Hutchinson-Gilford Progeria syndrome age prematurely due to a defective protein in their cells. Scientists at Technische Universität München have now identified another important pathological factor: the system responsible for removing cellular debris and for breaking down defective proteins operates at lower levels in HGPS cells than in normal cells. The researchers have succeeded in reactivating protein breakdown in HGPS cells and thus reducing disease-related defects by using a substance from broccoli.
New York Blood Center (NYBC), serving more than 20 million people in New York City, Long Island, the Hudson Valley, and New Jersey, calls upon our communities to please donate blood and platelets, after our tally of blood donations lost due to the weather doubled overnight – to more than 2,000.
Haiti, the U.S. and other international partners on Monday launched "a nationwide vaccination campaign in the Caribbean country that seeks to curb or prevent infectious diseases, health officials said," the Associated Press/Fox News reports.
Spectral Diagnostics Inc., a Phase III company seeking FDA approval for its lead theranostics product for the treatment severe sepsis and septic shock, today announced initiation of its U.S. pivotal trial of Toraymyxin™, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream, for patients with severe sepsis.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. announced today that it has submitted a New Drug Application to the U.S. Food and Drug Administration for rivaroxaban, an investigational, oral, once-daily anticoagulant, for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation.
› Verified 4 days ago
| Entity Name | Hartford Healthcare Medical Group Specialists Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023584216 PECOS PAC ID: 3173866241 Enrollment ID: O20190514001441 |
News Archive
Children who suffer from Hutchinson-Gilford Progeria syndrome age prematurely due to a defective protein in their cells. Scientists at Technische Universität München have now identified another important pathological factor: the system responsible for removing cellular debris and for breaking down defective proteins operates at lower levels in HGPS cells than in normal cells. The researchers have succeeded in reactivating protein breakdown in HGPS cells and thus reducing disease-related defects by using a substance from broccoli.
New York Blood Center (NYBC), serving more than 20 million people in New York City, Long Island, the Hudson Valley, and New Jersey, calls upon our communities to please donate blood and platelets, after our tally of blood donations lost due to the weather doubled overnight – to more than 2,000.
Haiti, the U.S. and other international partners on Monday launched "a nationwide vaccination campaign in the Caribbean country that seeks to curb or prevent infectious diseases, health officials said," the Associated Press/Fox News reports.
Spectral Diagnostics Inc., a Phase III company seeking FDA approval for its lead theranostics product for the treatment severe sepsis and septic shock, today announced initiation of its U.S. pivotal trial of Toraymyxin™, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream, for patients with severe sepsis.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. announced today that it has submitted a New Drug Application to the U.S. Food and Drug Administration for rivaroxaban, an investigational, oral, once-daily anticoagulant, for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Agata Joanna Sajkiewicz, MD 80 Seymour St, Hartford, CT 06102-8000 Ph: (203) 852-2471 | Agata Joanna Sajkiewicz, MD 34 Maple St, Norwalk Hospital, Norwalk, CT 06850-3815 Ph: (203) 852-2471 |
News Archive
Children who suffer from Hutchinson-Gilford Progeria syndrome age prematurely due to a defective protein in their cells. Scientists at Technische Universität München have now identified another important pathological factor: the system responsible for removing cellular debris and for breaking down defective proteins operates at lower levels in HGPS cells than in normal cells. The researchers have succeeded in reactivating protein breakdown in HGPS cells and thus reducing disease-related defects by using a substance from broccoli.
New York Blood Center (NYBC), serving more than 20 million people in New York City, Long Island, the Hudson Valley, and New Jersey, calls upon our communities to please donate blood and platelets, after our tally of blood donations lost due to the weather doubled overnight – to more than 2,000.
Haiti, the U.S. and other international partners on Monday launched "a nationwide vaccination campaign in the Caribbean country that seeks to curb or prevent infectious diseases, health officials said," the Associated Press/Fox News reports.
Spectral Diagnostics Inc., a Phase III company seeking FDA approval for its lead theranostics product for the treatment severe sepsis and septic shock, today announced initiation of its U.S. pivotal trial of Toraymyxin™, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream, for patients with severe sepsis.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. announced today that it has submitted a New Drug Application to the U.S. Food and Drug Administration for rivaroxaban, an investigational, oral, once-daily anticoagulant, for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation.
› Verified 4 days ago
Dr. Eve Block, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 24 Stevens St, Norwalk, CT 06850 Phone: 203-852-2665 Fax: 203-739-8878 | |
Vittoria Gassman, MD Internal Medicine Medicare: Medicare Enrolled Practice Location: 120 Connecticut Ave, Norwalk Community Health Center, Norwalk, CT 06854 Phone: 203-899-1770 | |
Dr. Yonatan J Hillman, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 30 Stevens St Ste D, Norwalk, CT 06850 Phone: 203-852-3455 | |
Maria A Martin, M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 761 Main Ave, Suite 201, Norwalk, CT 06851 Phone: 203-838-4000 Fax: 203-845-9535 | |
Xiaofei Wei, Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 761 Main Ave, Suite 201, Norwalk, CT 06851 Phone: 203-838-4000 Fax: 203-845-9535 | |
Daniel Ethan Boxer, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 24 Stevens St, Norwalk, CT 06850 Phone: 203-845-4811 Fax: 203-845-4897 | |
Dr. Caitlyn Kuwata, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 34 Maple St, Norwalk, CT 06850 Phone: 203-852-2025 |